Mast cells are a well-known immune cell responsible for combatting pathogens and mounting allergic responses. Mast Cell Activation Syndrome (MCAS) is a group of disorders where mast cells act abnormally and release excessive amounts of their chemical mediators. As mast cells are found all over the body, this causes widespread, multi-system effects from chronic inflammation, severe pain to anaphylaxis. In Australia, the prevalence of MCAS is not precisely documented, but its effect is profound. Estimates suggest that thousands of Australians may be affected, emphasising the need for research and innovative treatments to address the challenges posed by MCAS.

BRP-192 has a unique formulation containing a compound scientifically known as palmitoyl ethanolamide (PEA). In pre-clinical studies, PEA showcases the ability to down-modulate mast cell activity, which translates to less chemical mediators being released into the body. A lower amount of mediators would mean that the symptoms of MCAS, including neurogenic pain, could be alleviated. As such, BRP-192 offers a new hope to those suffering the symptoms of MCAS.